Aintree University Hospital NHS Foundation Trust v James: Best Interests and Futility under the Judicial Microscope

Guest post by Daniel Sokol, barrister at 12 King’s Bench Walk / King’s College London. Eight years after coming into force, the Mental Capacity Act 2005 has finally reached the scrutiny of the Supreme Court in Aintree University Hospital NHS Foundation Trust v James [2013] UKSC 67. David James was a professional musician, and a family […]

Read More…

Smoking out Tobacco Industry-Supported Research

BMJ Open, along with a couple of other journals, published a statement a couple of days ago saying that they’d no longer accept papers based on research wholly or partially funded by the tobacco industry.  The gloss on the statement is damning: The tobacco industry, far from advancing knowledge, has used research to deliberately produce ignorance […]

Read More…

How to write a crap essay/paper in bioethics – or how to write bioethics to be published in medical journals…

By David Hunter I’ve been considering writing a reflective piece about the general quality of bioethics papers in medical journals, focusing on how the medium (the audience and the severe word limits) impacts on the message and its quality – possibly as a bit of a moan since I’ve not yet managed to get a […]

Read More…

Under-Treatment, Treated.

Right: file this paper from the JAMA under “Properly Odd”.  It’s a proposal that nonadherence to a treatment regime be classed as a treatable medical condition in its own right. No, really.  Look at the title: “Medication Nonadherence: A Diagnosable and Treatable Medical Condition”. Starting from the fairly straightforward premise that non-adherence to treatment regimes is “a […]

Read More…

Research Ethics and Ethical Problems

Noted on Ben Goldacre’s twitter feed a couple of weeks ago was this article in Slate about the recruitment of pregnant women into drug trials. Essentially, there’s a situation in which there’s a dearth of information about the impact of drugs during pregnancy.  According to the article, [p]harmaceutical companies are not willing to navigate the […]

Read More…